In the following video, Fool contributor Maxxwell Chatsko recaps the latest earnings results from the pharmaceutical industry for investors. Some Big Pharma companies have traversed the patent cliff in relatively good shape with new therapies waiting in the wings to fill the void in sales. Others, such as AstraZeneca (NYSE:AZN) and Eli Lilly (NYSE:LLY), are just beginning their slide, but their immediate and long-term futures are more difficult to pin down.
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
- May 13, 2013 at 2:00PM
- Health Care